Covid-19 roundup: Pfiz­er rais­es 2021 vac­cine sales fore­cast to $36B; Lil­ly lands $1.3B treat­ment deal with US gov­ern­ment

Pfiz­er’s Covid-19 vac­cine in 2021 is quick­ly be­com­ing the best-sell­ing med­ical prod­uct of all time in terms of an­nu­al sales.

The com­pa­ny on Tues­day re­port­ed its quar­ter­ly earn­ings and re-upped its year­ly guid­ance on its Covid-19 vac­cine sales, say­ing the com­pa­ny an­tic­i­pates $36 bil­lion in 2021, up from its $33.5 bil­lion es­ti­mate in Ju­ly. The com­pa­ny ex­pects to de­liv­er a whop­ping 2.3 bil­lion dos­es of its vac­cine in 2021, but it ex­pects to man­u­fac­ture 3 bil­lion dos­es in to­tal by the end of De­cem­ber.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN